Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
Read original at benzingaStocks · News reference
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 7, 2026, 4:45 PM
- Checked
- Jul 7, 2026, 4:50 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Kailera Therapeutics, Inc. (KLRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346919 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarKailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China
Read original at benzinga